PI Industries announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company highlighted resilience in its business performance, underpinned by a diverse portfolio and strong customer relationships. Key growth drivers included a significant 40% growth in the Pharma business and strong momentum in its Biologicals segment. The company also detailed its strategic focus on innovation, particularly its New Chemical Entity (NCE) program, and its continued investment in R&D and manufacturing capabilities for future growth.
PI Industries Reports Q4 FY26 Earnings
PI Industries has released its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company’s earnings conference call provided insights into its performance and strategic direction.
Financial Highlights for FY26
The consolidated revenue for the full year FY26 reached ₹67,137 million, supported by healthy EBITDA margins of 25%. The company maintained a strong cash balance of INR 34,265 million, enabling future strategic investments for sustainable growth.
For Q4 FY26, revenue stood at ₹15,652 million, reflecting sequential growth as guided. The full-year revenue demonstrated growth on a 3-year CAGR.
Segment Performance and Growth Drivers
Pharma Business
The Pharma business exhibited strong growth, delivering 40% growth for the full year FY26. PI Industries continues to enhance customer engagement with innovator and biotech companies, investing in process development, regulatory systems, and commercial scale-up. The PI Health Sciences (PIHS) platform is identified as a strategically important long-term growth driver, leveraging deep chemistry capabilities and an integrated India-Italy operating model.
Biologicals
The Biologicals segment, a long-standing area of focus for PI, has emerged as one of its fastest-growing segments, compounding at over 20%. Strategic acquisitions of differentiated technology platforms have provided global market access and accelerated R&D capabilities, positioning the company for next-generation crop health solutions.
AgChem and New Initiatives
In AgChem, while exports saw a decline due to global industry contraction, the company launched 4 new products domestically (3 herbicides & 1 insecticide). New products now contribute 18% of AgChem Exports, indicating a focused derisking and innovation strategy.
A significant strategic initiative is the in-house New Chemical Entity (NCE) program. The first NCE, Pioxaniliprole, discovered in India, is slated for market launch, signifying PI’s shift towards global innovation and manufacturing.
Sustainability and Digital Transformation
PI Industries maintained its position in the S&P Global Sustainability Yearbook, with its S&P Global CSA percentile improving to 98 percentile. The company has also successfully implemented SAP S/4 Hana, a key milestone in its digital transformation journey, enhancing operational backbone and data visibility.
Future Outlook and Investment
Looking ahead to FY27, PI Industries anticipates positive growth, driven by the recovery in exports in the second half, new product launches, and the scaling up of its pharma and biologicals businesses.
Capital expenditure for FY27 is projected at INR 700 to INR 800 crore, allocated across manufacturing, new launches, and R&D for both pharma and agrochemical businesses. The company is also focusing on building capabilities in electronic chemicals, targeting a revenue of approximately $80 million to $100 million in this segment over the next 5-6 years.
The pharma business is projected to reach a revenue of INR 500 to INR 600 crore within the next 2-3 years, with a gradual move towards positive EBITDA.
Investor Call Key Takeaways
Management addressed questions regarding capex deployment, emphasizing a multi-year ramp-up for capacities and scale. The company highlighted its focus on innovation, particularly with its NCE program, and its strategy to build differentiated capabilities in emerging sectors like electronic chemicals and pharma.
Regarding margins, PI Industries aims to maintain gross margins around 58-59% and manage EBITDA margins amidst a volatile environment. The company is committed to holding market share and volume, with margins expected to rebound as market conditions improve.
The electronic chemicals segment is in its early stages, with a focus on building capacities and customer understanding. The company expects to provide a clearer picture on revenue figures for this segment in the next 2-3 years.
In the global biologicals business, break-even is anticipated within the next couple of years, supported by product registrations and expanding distribution networks.
Source: BSE
